Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

National Surveillance for Clostridioides difficile Infection, Sweden, 2009-2016.

Rizzardi K, Norén T, Aspevall O, Mäkitalo B, Toepfer M, Johansson Å, Åkerlund T.

Emerg Infect Dis. 2018 Sep;24(9):1617-1625. doi: 10.3201/eid2409.171658.

2.

Increased number of Campylobacter bacteraemia cases in Sweden, 2014.

Harvala H, Ydring E, Brytting M, Söderblom T, Mäkitalo B, Wallensten A, Wisell KT, Jernberg C.

Clin Microbiol Infect. 2016 Apr;22(4):391-393. doi: 10.1016/j.cmi.2015.11.013. Epub 2015 Dec 11. No abstract available.

3.

Carbapenemase-producing Enterobacteriaceae in Sweden 2007-2013: Experiences from seven years of systematic surveillance and mandatory reporting.

Löfmark S, Sjöström K, Mäkitalo B, Edquist P, Tegmark Wisell K, Giske CG.

Drug Resist Updat. 2015 May;20:29-38. doi: 10.1016/j.drup.2015.05.001. Epub 2015 May 11.

PMID:
26004211
4.

Epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in Sweden 2007-2011.

Brolund A, Edquist PJ, Mäkitalo B, Olsson-Liljequist B, Söderblom T, Wisell KT, Giske CG.

Clin Microbiol Infect. 2014 Jun;20(6):O344-52. doi: 10.1111/1469-0691.12413. Epub 2013 Nov 18.

5.

Immunization with apoptotic pseudovirus transduced cells induces both cellular and humoral responses: a proof of concept study in macaques.

Koopman G, Beenhakker N, Hofman S, Walther-Jallow L, Mäkitalo B, Mooij P, Anderson J, Verschoor E, Bogers WM, Heeney JL, Spetz AL.

Vaccine. 2012 Mar 28;30(15):2523-34. doi: 10.1016/j.vaccine.2012.01.082. Epub 2012 Feb 5.

PMID:
22314133
6.

Exposure to apoptotic activated CD4+ T cells induces maturation and APOBEC3G-mediated inhibition of HIV-1 infection in dendritic cells.

Mohanram V, Johansson U, Sköld AE, Fink J, Kumar Pathak S, Mäkitalo B, Walther-Jallow L, Spetz AL.

PLoS One. 2011;6(6):e21171. doi: 10.1371/journal.pone.0021171. Epub 2011 Jun 16.

7.

Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule.

Josefsson L, King MS, Makitalo B, Brännström J, Shao W, Maldarelli F, Kearney MF, Hu WS, Chen J, Gaines H, Mellors JW, Albert J, Coffin JM, Palmer SE.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11199-204. doi: 10.1073/pnas.1107729108. Epub 2011 Jun 20.

8.

Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.

Ozkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Sheik-Khalil E, Taylor S, Pybus OG, Mäkitalo B, Walther-Jallow L, Spångberg M, Thorstensson R, Achour A, Fenyö EM, Stewart-Jones GB, Spetz AL.

PLoS Pathog. 2010 Sep 2;6(9):e1001084. doi: 10.1371/journal.ppat.1001084.

9.

Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.

Hinkula J, Walther-Jallow L, Laurén A, Mäkitalo B, Oberg M, Wahren B, Fenyö EM, Spetz AL.

Vaccine. 2009 Oct 30;27(46):6424-31. doi: 10.1016/j.vaccine.2009.06.016. Epub 2009 Jun 21.

PMID:
19549607
10.

A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry.

Godoy-Ramirez K, Mäkitalo B, Thorstensson R, Sandström E, Biberfeld G, Gaines H.

Cytometry A. 2005 Dec;68(2):71-80.

11.

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

Mäkitalo B, Lundholm P, Hinkula J, Nilsson C, Karlén K, Mörner A, Sutter G, Erfle V, Heeney JL, Wahren B, Biberfeld G, Thorstensson R.

J Gen Virol. 2004 Aug;85(Pt 8):2407-19.

PMID:
15269383
12.

ELISpot and ELISA analysis of spontaneous, mitogen-induced and antigen-specific cytokine production in cynomolgus and rhesus macaques.

Mäkitalo B, Andersson M, Areström I, Karlén K, Villinger F, Ansari A, Paulie S, Thorstensson R, Ahlborg N.

J Immunol Methods. 2002 Dec 1;270(1):85-97.

PMID:
12379341
13.

A novel potent strategy for induction of immunity to HIV-1 reverse transcriptase in primates.

Zuber B, Mäkitalo B, Zuber AK, Wahren B.

AIDS. 2002 Sep 6;16(13):1839-40. No abstract available.

PMID:
12218401
14.
15.

Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys.

Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R.

J Gen Virol. 2001 Jul;82(Pt 7):1601-12.

PMID:
11413371
16.

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.

Nilsson C, Mäkitalo B, Berglund P, Bex F, Liljeström P, Sutter G, Erfle V, ten Haaft P, Heeney J, Biberfeld G, Thorstensson R.

Vaccine. 2001 May 14;19(25-26):3526-36.

PMID:
11348720
17.

Cell-mediated immunity to low doses of SIVsm in cynomolgus macaques did not confer protection against mucosal rechallenge.

Mäkitalo B, Böttiger1 P, Biberfeld G, Thorstensson R.

Vaccine. 2000 Sep 15;19(2-3):298-307.

PMID:
10930685
18.

Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm.

Nilsson C, Mäkitalo B, Thorstensson R, Norley S, Binninger-Schinzel D, Cranage M, Rud E, Biberfeld G, Putkonen P.

AIDS. 1998 Dec 3;12(17):2261-70.

PMID:
9863867
19.

Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission.

Putkonen P, Mäkitalo B, Böttiger D, Biberfeld G, Thorstensson R.

J Virol. 1997 Jul;71(7):4981-4.

20.

Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys.

Andersson S, Mäkitalo B, Thorstensson R, Franchini G, Tartaglia J, Limbach K, Paoletti E, Putkonen P, Biberfeld G.

J Infect Dis. 1996 Nov;174(5):977-85.

PMID:
8896498

Supplemental Content

Loading ...
Support Center